ALT
NASDAQ · Biotechnology
Altimmune Inc
$3.09
+0.05 (+1.64%)
Open$3.07
Previous Close$3.04
Day High$3.11
Day Low$3.01
52W High$7.73
52W Low$2.56
Volume—
Avg Volume5.75M
Market Cap600.56M
P/E Ratio—
EPS$-1.00
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+241.4% upside
Current
$3.09
$3.09
Target
$10.55
$10.55
$6.68
$10.55 avg
$11.58
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 97.2K | 232.2K | 252.74M |
| Net Income | -194,335,742 | -932,514,656 | 22.15M |
| Profit Margin | -214,861.0% | -451,530.3% | 8.8% |
| EBITDA | -208,620,848 | -1,065,342,972 | 31.01M |
| Free Cash Flow | — | — | 16.83M |
| Rev Growth | — | -83.5% | +1.7% |
| Debt/Equity | 0.15 | — | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |